search button

The use of treosulfan and gemcitabine in the treatment of platinum-resistant ovarian cancer

  • Authors:
    • S. Hilman
    • PK. Koh
    • S. Collins
    • R. Allerton

  • View Affiliations

  • Published online on: January 1, 2010     https://doi.org/10.3892/ol_00000038
  • Pages: 209-213
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The combination of treosulfan and gemcitabine (TG) has been shown to have activity in ovarian cancer. These two agents are thought to be synergistic, with gemcitabine causing the persistence of treosulfan-induced DNA crosslinks. This study aimed to investigate the response rates, survival and toxicity in patients with platinum-resistant ovarian cancer treated with TG. A retrospective case note review of the patients treated with TG was performed in one cancer centre between May 1st, 2000 and November 1st, 2005. Estimates of cumulative survival were obtained using the Kaplan-Meier method. Forty-nine patients were identified; median age at diagnosis was 55 years (range, 31-72) and the median follow-up was 45.1 months (range, 12.2-118.3). TG was used as second-, third-, fourth- and fifth-line chemotherapy in 15, 19, 13 and 2 patients, respectively. Fifteen patients (30.6%) had stable disease; 25 (51%), a partial response; 1 (2%), a complete response and 8 (16.3%) had progressive disease. Median survival following diagnosis was 45.1 months and the median relapse-free survival was 12 months. The median survival time from the start of TG was 13.7 months with a relapse-free survival of 6.3 months. The median number of cycles given was 7. The most common toxicity recorded was myelosuppression. There were no treatment-related deaths. TG chemotherapy produced favourable response rates in a heavily pre-treated group of patients with platinum-resistant epithelial ovarian cancer. This doublet warrants further investigation in a phase III trial setting.
View Figures
View References

Related Articles

Journal Cover

January-February 2010
Volume 1 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.5
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 5.7
  • CiteScore Rank: Q2: #139/404 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.574
  • SCImago Journal Rank (SJR): 0.644
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Hilman S, Koh P, Collins S and Allerton R: The use of treosulfan and gemcitabine in the treatment of platinum-resistant ovarian cancer . Oncol Lett 1: 209-213, 2010.
APA
Hilman, S., Koh, P., Collins, S., & Allerton, R. (2010). The use of treosulfan and gemcitabine in the treatment of platinum-resistant ovarian cancer . Oncology Letters, 1, 209-213. https://doi.org/10.3892/ol_00000038
MLA
Hilman, S., Koh, P., Collins, S., Allerton, R."The use of treosulfan and gemcitabine in the treatment of platinum-resistant ovarian cancer ". Oncology Letters 1.1 (2010): 209-213.
Chicago
Hilman, S., Koh, P., Collins, S., Allerton, R."The use of treosulfan and gemcitabine in the treatment of platinum-resistant ovarian cancer ". Oncology Letters 1, no. 1 (2010): 209-213. https://doi.org/10.3892/ol_00000038